Sarah Tasian, MD, Children's Hospital of Philadelphia, Philadelphia, PA, shares some insights into the Phase II AALL1521 trial (NCT02723994), which is evaluating whether the addition of ruxolitinib to chemotherapy may improve outcomes for pediatric patients with Philadelphia chromosome (Ph)-like acute lymphoblastic leukemia (ALL). This interview took place at the 64th ASH Annual Meeting and Exposition congress held in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
